Purpose: The purpose of this study is to compare treatment outcomes of methotrexate, cisplatin, and 5-fluorouracil (MPF) or cisplatin and 5-fluorouracil (PF) in pediatric NPC patients treated with sequential chemoradiotherapy.
(J Pediatr Hematol Oncol 2017;39:e437-e442) N asopharyngeal carcinoma (NPC) is a rare pediatric malignancy contributing <1% of all pediatric tumors. 1, 2 NPC is endemic in southern China and Asia, but rare in Europe and North America with an incidence <1 in 100,000. [2] [3] [4] [5] [6] The World Health Organization (WHO) classifies NPC into 3 types: squamous cell carcinoma (type I), keratinizing undifferentiated carcinoma (type II) and nonkeratinizing undifferentiated carcinoma (type III). 7 WHO type III, which is strongly associated with Epstein-Barr virus (EBV), is the most common subtype in children.
Treatment of pediatric NPC patients is not standardized because of limited prospective studies in this disease. Secondary to molecular and biological characteristics, NPC is relatively sensitive to chemoradiotherapy, 8 with evidence to support cisplatin-based induction chemotherapy followed by radiotherapy. 3 Induction chemotherapy with methotrexate, cisplatin, and 5-fluorouracil (MPF) followed by radiotherapy was established as an accepted treatment option associated with long-term event-free survival (EFS) and overall survival (OS) in a seminal Pediatric Oncology Group phase II study. 9 Further, an international randomized phase II study failed to detect any added efficacy, when docetaxel was added to an induction chemotherapy regimen consisting of PF followed by concurrent chemoradiotherapy. 10 However, in patients treated with sequential chemoradiotherapy (induction chemotherapy followed by radiotherapy), according to our knowledge there are no previously-published studies which have compared induction chemotherapy regimens. Further, very little is known about the natural history, presentation, treatment and outcome of this disease in the Middle East. The aim of this study is to compare the therapeutic efficacy of induction chemotherapy regimens (MPV vs. PF) and report the clinical outcomes and prognostic factors of survival for pediatric NPC treated with induction chemotherapy followed by radiotherapy in a tertiary cancer center in Jordan.
PATIENTS AND METHODS
Between 2003 and 2009, NPC patients aged 18 years or below treated at King Hussein Cancer Center (Amman, Jordan) were identified by retrospective review of patient records. Patients were eligible if they had biopsy-proven, previously-untreated stage II-IV (American Joint Committee on Cancer, 6th edition) NPC and treated with curative intent using induction chemotherapy followed by radiotherapy. This study was approved by the institutional review board. All patients granted written informed clinical treatment consent before the start of their treatment.
Typical pretreatment assessments included complete history and physical examination, fiber-optic nasopharyngoscopy, routine blood tests, magnetic resonance imaging (MRI) of head and neck, computed tomography (CT) of the chest, abdomen and pelvis, and whole-body bone scan. In addition, all patients underwent pretreatment cardiac assessment, audiogram, dental evaluation, and nutritional assessment. All cases were discussed at a pediatric oncology multidisciplinary meeting, before initiation of therapy. Therapeutic radiologic response, evaluated using RECIST criteria (version 1.1), 11 was documented following 4 cycles of indication and at 6 to 8 weeks postradiotherapy. Patients who achieved less than complete response (CR) after radiotherapy were subsequently treated with palliative chemotherapy.
Induction Chemotherapy
Two induction chemotherapy protocols were used in this study. 
Radiotherapy
Radiotherapy was initiated 1 month after completion of induction chemotherapy and delivered by 3-dimensional conformal radiotherapy (3D-CRT) using once-daily fractions, 5 days a week. Total radiotherapy dose was determined based on induction chemotherapy response. Patients with CR or partial response (PR) received 61.2 Gy in 34 fractions whereas patients with stable disease (SD) or progressive disease (PD) received 66.6 Gy in 37 fractions. An elective radiotherapy dose of 45 Gy in 25 fractions to bilateral neck nodes and areas at risk for local tumor spread was delivered in all patients. Patients were immobilized in the supine position with a custom aquaplastic head and neck mask. Target localization was accomplished with CT simulation using 5 mm thick slices extending from the vertex to 5 cm inferior to the clavicular heads. Target volume definition was guided by preinduction chemotherapy MRI, which was manually registered with planning CT. The gross tumor volume (GTV), which included primary nasopharyngeal tumor and lymph nodes greater than 1 cm or any node with necrotic center, was delineated. The clinical target volume (CTV) denoted the subclinical regions at risk for tumor spread. Different CTVs were defined as follows: CTV61.2 (in patients with CR or PR)/66.6 (in patients with SD or PD)−Primary = GTV+5 mm isotropic margin around primary tumor, CTV61.2/66.6−Nodal = GTV+5 mm isotropic margin around gross nodes, CTV45 = GTV−Primary/ Nodal+1 cm margin+areas at risk for microscopic involvement (entire nasopharyngeal mucosa, skull base, half of clivus in early-stage/whole clivus in T3-4 disease, pterygoid fossae, bilateral parapharyngeal spaces, sphenoid sinus, posterior third of the nasal cavity/maxillary sinuses including the pterygopalatine fossae, lateral retropharyngeal nodal region and levels Ib-V [node positive] or II-V [node negative]). To account for uncertainties of daily set-up, a planning target volume (PTV) of 5 mm was added to each of the above CTVs. Symptomatic supportive therapy was prescribed as required during treatment. Acute radiotherapy toxicity was not completely reported but late radiotherapy toxicity was retrieved and recorded as present (if the patient reported any significant symptoms, affection of quality of life or required treatment) or absent.
Follow-up
Patients were followed up weekly during radiotherapy, 2 weeks postradiotherapy, at 3 monthly intervals for the first 2 years and then at 4 monthly intervals for the third year. Follow-up consisted of physical examination, endoscopic examination, and laboratory tests. Head and neck MRI was performed every 6 months for 2 years and then annually or as clinically indicated.
Statistical Analysis
OS was defined as the time from diagnosis to death, from any cause. Patients who remained alive were censored at the date of their last follow-up. EFS was defined as the time from diagnosis to the first progression or relapse at any site or death from any cause. Patients who remained alive without disease progression or relapse were censored at the date of their last follow-up. Survival analyses were estimated using the KaplanMeier method. Patient groups were compared in terms of survival using the log rank test. Cox regression model was used to identify significant prognostic factors. Age, stage, radiation dose, and chemotherapy regimen were tested as prognostic factors for EFS and OS on univariate and multivariate analyses. Statistical significance was accepted when the P-value was <0.05. Statistical analysis was performed using SAS version 9.4 (SAS Institute Inc., Cary, NC).
RESULTS
Over the study period, 28 eligible patients were identified from the chart review. Three patients had no follow-up information and were excluded; 25 patients were included in the analysis. All patients had undifferentiated NPC (WHO type III). EBV testing was not routinely performed during the study period. The majority were males (n = 16). The median age at diagnosis was 13.3 years (range, 7 to 17.1 y). Two patients harbored stage II (8%), 13 stage III (52%), and 10 stage IV (40%). Bilateral neck swelling (59%), hearing loss (26%), and epistaxis (19%) were the most common presenting symptoms. The median time between onset of symptoms and diagnosis was 14 weeks (range, 4 to 52 wk). Baseline patient characteristics are summarized in Table 1 . As shown, the majority of patients above 14 years were treated with MPF (88.9%) compared with PF (37.5%) induction chemotherapy (P = 0.033). This difference was also reflected in varying patient height and weight at diagnosis for the 2 chemotherapy cohorts. Follow-up for patients treated with MPF was significantly longer (median, 86.4 mo) compared with patients treated with PF (median, 48 mo) induction chemotherapy (P = 0.0435).
All patients completed 4 cycles of chemotherapy, as planned. All patients who received MPF achieved PR whereas 15 patients (93.8%) achieved PR in the PF group (P = 1). One patient had PD following PF and was switched to gemcitabine and carboplatin with SD thereafter. On follow-up imaging 6 to 8 weeks after completion of radiotherapy, CR was documented in 19 patients (76%), PR in 4 patients (16%), whereas PD was observed in 2 patients (8%). There was no difference in radiologic response postradiotherapy between the 2 chemotherapy groups ( Table 2) .
After a median follow-up of 56 months (range, 14 to 103 mo), 19 patients (76%) were alive of whom, 17 (68%) with no evidence of disease. The 5-year EFS was 67.56% (Fig. 1A) whereas the 5-year OS was 75.79% (Fig. 1B) for the whole patient population. Patients aged 14 years or younger (cf, > 14 y) had better EFS (90.91% vs. 48.98% at 5 y, respectively; P = 0.02). Superior EFS (86.15% vs. 40% at 5 y; P = 0.01) and OS (92.86% vs. 50% at 5 y; P = 0.01) was seen for patients with stage II-III versus IV, respectively. There were no differences in EFS (68.75% vs. 66.67% at 5 y; P = 0.84) and OS (81.25% vs. 66.67% at 5 y; P = 0.39) between PF versus MPF, respectively (Fig. 2) . Similarly, there were no differences in EFS (71.43% vs. 70.59% at 5 y; P = 0.97) and OS (71.43% vs. 82.35% at 5 y; P = 0.54) between 66.2 Gy vs. 61.2 Gy, respectively. There was no difference in EFS and OS between male and female genders. On multivariate analysis, only tumor stage (IV vs. II-III) predicted worse OS (hazard ratio, 10.3; 95% confidence interval (CI);, 1.197-88.974) but not EFS (hazard ratio, 4.805; 95% CI, 0.95-24.336; Table 3 ). Eight patients (32%) had disease recurrent disease on followup (5 [31.3%] in the PF and 3 [33%] in the MPF group; P = 1). The pattern of treatment failure is shown in Table 4 . Overall, distant metastases was the predominant site of failure seen in 5 patients (20%).
In the whole study population, the following late radiotherapy-related side-effects were recorded: hypothyroidism in 10 patients: transient (n = 2), xerostomia (n = 9), dysphagia (n = 8), dental pain (n = 8), hearing loss (n = 4), trismus (n = 4), and neck fibrosis, hypogonadotropic hypogonadism, short stature, behavior problems, depression, neck pain, leukodystrophy, malnutrition, and nasal speech each seen in 1 patient.
DISCUSSION
The incidence of pediatric NPC varies widely according to racial and geographical factors. We treat around 4 to 7 pediatric NPC cases every year. It is noteworthy that in Jordan, the overwhelming majority of pediatric cancer patients are treated at our tertiary cancer referral center. This study revealed a peak presentation in late childhood and male predominance, both findings were reported in previous studies. 1, 3, 5, 12, 13 Further, all patients were diagnosed with WHO type III tumors, a finding also similar to previous pediatric NPC studies. 14, 15 Patients with WHO type III tumors are more likely to present with advanced stage at presentation. 14 In our study, 23 patients (92%) harbored stage III/IV disease. EBV is endemic in Jordan, positive staining for EBV by in situ hybridization was seen in 92.3% of NPC specimens in Jordan. 16 Unfortunately, EBV status was not available in our study. Cervical lymphadenopathy is the most common presenting symptom of NPC. Other symptoms include nasal obstruction, epistaxis, headache, and auditory dysfunction. 6 Bilateral neck swelling (59%), hearing loss (26%), and epistaxis (19%) were the most common presenting symptoms in our study. Clinical stage and age below 12 years were shown to be associated with improved OS and EFS in a relatively large analysis of 95 patients with NPC below 20 years of age. 17 In our study, patients aged 14 years or below had significantly better EFS compared with their older counterparts. It is unclear whether this finding could be explained by varying molecular tumor characteristics in younger patients. A systematic review and meta-analysis revealed that patients treated with combined radiotherapy and chemotherapy achieved better outcomes compared with those treated with radiotherapy alone. 18 This study showed that the mean disease-free survival rate was 66% (95% CI, 56-76%) among 15 studies which included 865 patients. Induction chemotherapy with MPF followed by radiotherapy was associated with 4-year EFS and OS rate of 77% and 75%, respectively, in a seminal Pediatric Oncology Group phase II study. 9 Further, few studies have shown good outcomes with induction chemotherapy followed by concurrent chemoradiotherapy. 19, 20 A recently reported international randomized phase 2 study failed to detect any added efficacy, evaluated by achievement of CR, when docetaxel was added to an induction chemotherapy regimen consisting on PF followed by concurrent chemoradiotherapy. 10 Excellent outcomes (OS and EFS rates, > 90%) are achievable with the use of chemotherapy, radiotherapy, and adjuvant interferon (IFN)-beta, 21, 22 but this treatment is not widely adopted in many developing countries or lessadvanced cancer centers because of financial considerations or lack of expertise.
Very few robust evidence exists to guide the choice of induction chemotherapy regimen in pediatric NPC patients treated with radiotherapy. Younger patients are at higher risk of developing treatment-related complications 23 particularly related to radiotherapy. 14 In 2007, we omitted methotrexate form the induction chemotherapy regimen for pediatric patients with NPC in an attempt to decrease treatment-related side-effects. Although the rate of radiologic tumor response was nonstatistically higher in patients who received MPF versus PF induction chemotherapy in our study, we failed to detect any significant survival difference between the 2 regimens in pediatric NPC patients. Our findings also demonstrate that acceptable results can be reproduced in developing countries, in lieu of international randomized trials, with both induction chemotherapy regimens suggesting appropriate omission of methotrexate in these patients. Distant metastases remains the main failure site in patients treated with induction chemotherapy followed by radiotherapy/chemoradiotherapy. 24 This was also confirmed in our study where 5 patients (20%) developed distant metastases.
A radiation dose > 65 Gy is associated with improved local tumor control, albeit results are inconsistent across studies. 18 Good response to induction chemotherapy is an important prognosticator and radiotherapy dose reduction has been proposed for these patients. 25 The GPOH-NPC Study Group now recommends that radiotherapy doses can be safely reduced to 59.4 to 54.4 Gy in patients who achieve CR on positron emission tomography following induction PF when treated with concurrent chemoradiotherapy. 26 We have elected not reduce our radiotherapy dose, as following induction chemotherapy, our patients are treated with radiotherapy alone.
The use of intensity-modulated radiotherapy has been proposed to improve target coverage and decrease radiotherapy-related side-effects. [27] [28] [29] This is particularly true in pediatric NPC patients as most are locally-advanced at diagnosis. 30 Although complete information regarding radiotherapy side-effects were missing from our study (eg, grading not available), we reported a relatively high rate of late radiotherapy-related side-effects during the study period. At the time of this study, our pediatric NPC patients were treated using 3D-CRT technique. Recently, we adopted intensity-modulated radiotherapy as the standard radiotherapy delivery technique for these patients and anticipate that this will result in lower incidence of late xerostomia, dysphagia, and hearing loss and possibly, improved target volume coverage.
There are a number of limitations of this study. This study included a relatively small number of patients, treated in a single center over an extended period of time (2003 to 2009). Chemotherapy-related side-effects were also not available in this study. As such, we are unable to confirm whether the omission of methotrexate leads to less treatment-related toxicity. Further, a larger percentage of patients aged above 14 years were treated using MPF, whereas the omission of methotrexate later in the study led to a shorter follow-up for those treated with PF chemotherapy. To overcome these limitations, there is a strong need for large, international collaborative studies in this disease. 31 In the Middle East and developing countries with limited resources, induction chemotherapy using PF followed by radiotherapy is a valid treatment option in pediatric NPC patients. We have shown that the omission of methotrexate from the induction chemotherapy regimen did not affect treatment outcome. A relatively high rate of distant metastases was demonstrated in our patients, development of more effective but economical systemic therapies should become a research priority. 
